Key Inclusion Criteria:

          1. For Dose Escalation Only: any locally advanced or metastatic, histologically or
             cytologically proven solid tumor or NHL, relapsed after or progressing despite
             conventional treatment

          2. Life expectancy of at least 12 weeks

          3. World Health Organization (WHO) performance status of 0-1

          4. Must meet select hematological and biochemical laboratory indices

          5. Archival tumor tissue or accessible tumor and willingness to consent to a biopsy

        Expansion Only:

          1. Any locally advanced or metastatic malignancy of the following types for which no
             other conventional therapy is considered appropriate:

               -  Metastatic Colorectal Cancer (CRC)

               -  Platinum-resistant or intolerant High Grade Serious Ovarian Cancer (HGSOC)

               -  Advanced Non-Small Cell Lung Cancer (NSCLC)

               -  Metastatic Castration-Resistant Prostate Cancer (mCRPC)

               -  Head and Neck Squamous Cell Carcinoma (HNSCC) or squamous cell carcinoma of the
                  anus (SCCA).

               -  Eligibility may be further restricted by the select number of prior regimens
                  specific to each indication

          2. Measurable disease per RECIST v1.1, or for mCRPC, evaluable disease per any of the
             following:

               -  Measurable disease per RECIST v1.1

               -  Increasing PSA

               -  Circulating tumor cell (CTC) count of 5 or more cells per 7.5 ml of blood

          3. Tumor tissue or ctDNA evidence that subject's tumor harbors a combination of mutations
             which are expected to confer sensitivity to Chk1 inhibition. Eligibility will be
             determined by the Sponsor's review of genetic abnormalities detected in genes in the
             following categories:

               -  Oncogenic drivers such as MYC, CCNE1, etc.

               -  Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as
                  RAD50, TP53, etc. For patients with NHSCC or SCCA, positive HPV status is also
                  considered for eligibility.

               -  The DDR pathway including BRCA1, BRCA2 and FANC. For patients with CRC, MMR
                  genetic alterations and/or high microsatellite instability are also considered
                  for eligibility.

               -  Genetic indicators of replicative stress such as gain of function/amplification
                  of Chk1 or ATR or other related gene.

        Key Exclusion Criteria:

          1. Received the following prior or current anticancer therapy:

               -  Radiotherapy within the last 6 weeks

               -  Endocrine therapy during the previous 4 weeks

               -  Chemotherapy during the previous 4 weeks

               -  Immunotherapy during the previous 6 weeks

               -  Nitrosoureas or Mitomycin C during the previous 6 weeks

               -  Other Investigational Medicinal Product during the 4 weeks before treatment

               -  Any prior treatment with a Chk1 inhibitor or prior treatment with an ATR
                  inhibitor within 6 months prior to receiving SRA737

          2. Other malignancy within the past 2 years, except for adequately treated tumors

          3. Ongoing toxic manifestations of previous treatments greater than NCI-CTCAE Grade 1

          4. For Dose Escalation: new or progressing brain metastases. For Cohort Expansion:
             present or prior brain metastases

          5. High medical risk because of nonmalignant systemic disease

          6. Serologically positive for hepatitis B, hepatitis C or HIV

          7. Serious cardiac condition, left ventricular ejection fraction < 45% at baseline,
             history of cardiac ischemia within the past 6 months, or prior history of cardiac
             arrhythmia requiring treatment

          8. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone
             marrow within 8 weeks

          9. Peanut allergy

         10. QTcF> 450 msec in adult males and > 470 msec in adult females

         11. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of SRA737

         12. Inability to swallow capsules without chewing or crushing

         13. Is a participant or plans to participate in another interventional clinical trial

         14. Any other condition which in the Investigator's opinion would not make the subject a
             good candidate